BridgeBio Pharma
Latest round
- Series D
Last raised
- Jan 2019
Total raised
- $434M
Investors
- 9
About BridgeBio Pharma
D., BridgeBio Pharma, Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing genetically targeted therapies for patients with genetic diseases related to cardiology, neurology, oncology, dermatology, and the endocrine system. In January 2024, BridgeBio Pharma, Inc. The company provides a wide range of genetic disease therapies, such as NULIBRYTM (fosdenopterin), and focuses on advancing potential therapies for genetic conditions and cancers with genetic drivers. Additionally, the firm also provides patient advocacy and clinical trial development services.
Who invested in BridgeBio Pharma
9 investors across 2 rounds
See all investors in BridgeBio Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BridgeBio Pharma
Who invested in BridgeBio Pharma?
BridgeBio Pharma has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BridgeBio Pharma raised?
BridgeBio Pharma has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did BridgeBio Pharma last raise money?
BridgeBio Pharma's most recent round on record is a Series D, in Jan 2019.
What does BridgeBio Pharma do?
BridgeBio Pharma is a biotechnology company.
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, US.
Which VCs invest in companies like BridgeBio Pharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at BridgeBio Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like BridgeBio Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.